HDV
MCID: HPT015
MIFTS: 49

Hepatitis D (HDV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis D

MalaCards integrated aliases for Hepatitis D:

Name: Hepatitis D 12 74 52 43 15
Delta Hepatitis 12 52
Hepatitis Delta 58 54
Hepatitis D Infection 71
Hepatitis D Virus 58
Hdv 58

Classifications:

Orphanet: 58  
Rare hepatic diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:2047
MeSH 43 D003699
ICD10 via Orphanet 33 B17.0
UMLS via Orphanet 72 C0011226
Orphanet 58 ORPHA402823
UMLS 71 C0011226

Summaries for Hepatitis D

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis delta virus, which is an incomplete virus that requires the helper function of Hepatitis B virus to replicate and only occurs among people who are infected with the Hepatitis B virus. The infection has symptom fatigue, has symptom lethargy, has symptom anorexia, has symptom nausea, has symptom jaundice, has symptom clay-colored stools, has symptom dark urine, has symptom changes in personality, has symptom disturbances in sleep, has symptom confusion, has symptom abnormal behavior, has symptom somnolence, and has symptom coma.

MalaCards based summary : Hepatitis D, also known as delta hepatitis, is related to hepatitis and hepatitis b, and has symptoms including fatigue, jaundice and anorexia. An important gene associated with Hepatitis D is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Interferon gamma signaling. The drugs Peginterferon alfa-2a and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Hepatitis D (hepatitis delta) is a disease caused by the hepatitis D virus (HDV), a small spherical... more...

Related Diseases for Hepatitis D

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis D via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.0 IFNA2 IFNA1 GPT F2 EIF2AK2
2 hepatitis b 30.6 IFNA2 IFNA1 GPT F2 EIF2AK2
3 hepatitis a 30.4 IFNA2 IFNA1 GPT F2
4 infantile liver failure syndrome 1 30.1 GPT F2
5 viral hepatitis 30.1 IFNL3 IFNA2 IFNA1 GPT F2 CD40LG
6 hepatitis e 30.0 GPT F2 CD40LG
7 hepatic coma 30.0 GPT F2
8 hepatitis c 29.9 IFNA2 IFNA1 GPT EIF2AK2
9 acquired immunodeficiency syndrome 29.9 IFNA2 IFNA1 CD40LG
10 schistosomiasis 29.9 GPT F2 CD40LG
11 portal hypertension 29.9 IFNL3 GPT F2 CD40LG
12 hepatitis c virus 29.9 IFNL3 GPT EIF2AK2 ADAR
13 splenomegaly 29.8 IFNA2 IFNA1
14 drug-induced hepatitis 29.8 IFNL3 GPT CYP2D6 CYP2C9
15 esophageal varix 29.7 GPT F2
16 thrombocytopenia 29.6 IFNA2 IFNA1 GPT F2 CD40LG
17 hypothyroidism 29.5 IFNA2 IFNA1 GPT F2
18 viral infectious disease 29.5 IFNA2 IFNA1 GPT EIF2AK2 CD40LG
19 bilirubin metabolic disorder 29.5 SLC35A2 GPT F2 CD40LG
20 thalassemia 29.4 HBE1 GPT F2
21 autoimmune hepatitis 29.2 IFNA1 GPT F2 CYP2D6 CD40LG
22 portal vein thrombosis 29.1 IFNA2 IFNA1 F2 CYP2C9 CD40LG
23 diarrhea 29.0 SLC10A2 IFNA1 GPT CYP2D6 CD40LG
24 stomatitis 29.0 IFNA2 IFNA1 EIF2AK2 CD40LG ADAR
25 porphyria, acute hepatic 11.3
26 corneal intraepithelial neoplasm 10.5 IFNA2 IFNA1
27 lymphomatoid granulomatosis 10.5 IFNA2 IFNA1
28 epstein-barr virus hepatitis 10.5 GPT CD40LG
29 heterophyiasis 10.5 GPT CD40LG
30 hepatoportal sclerosis 10.5 GPT F2
31 emphysematous cholecystitis 10.4 GPT F2
32 granulomatous hepatitis 10.4 GPT CD40LG
33 hepatic infarction 10.4 GPT F2
34 gastrointestinal tuberculosis 10.4 GPT CD40LG
35 pyridoxine deficiency anemia 10.4 GPT F2
36 hepatic tuberculosis 10.4 GPT F2
37 discoid lupus erythematosus 10.4 IFNA2 IFNA1
38 fournier gangrene 10.4 F2 CD40LG
39 ascending cholangitis 10.4 GPT F2
40 liver leiomyosarcoma 10.4 GPT F2
41 giant hemangioma 10.4 IFNA2 F2
42 hydrops of gallbladder 10.4 GPT CD40LG
43 livedoid vasculitis 10.4 F2 CD40LG
44 squamous papillomatosis 10.4 IFNA2 IFNA1
45 intracranial sinus thrombosis 10.4 F2 CD40LG
46 acute cholangitis 10.4 GPT F2
47 viral laryngitis 10.4 GPT CD40LG
48 pyuria 10.4 GPT CD40LG
49 volkmann contracture 10.4 F2 CD40LG
50 paralytic ileus 10.4 GPT F2

Graphical network of the top 20 diseases related to Hepatitis D:



Diseases related to Hepatitis D

Symptoms & Phenotypes for Hepatitis D

Symptoms:

12 (show all 13)
  • fatigue
  • jaundice
  • anorexia
  • confusion
  • coma
  • lethargy
  • nausea
  • dark urine
  • clay-colored stools
  • changes in personality
  • disturbances in sleep
  • abnormal behavior
  • somnolence

GenomeRNAi Phenotypes related to Hepatitis D according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.53 EIF2AK2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 9.53 ADAR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.53 EIF2AK2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.53 CYP2D6
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 9.53 IFNA2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.53 CYP2D6
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.53 CYP2D6
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.53 ADAR CYP2D6 EIF2AK2 IFNA2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.53 IFNA2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.53 ADAR
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.53 CYP2D6
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.53 ADAR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-62 9.53 IFNA2

Drugs & Therapeutics for Hepatitis D

Drugs for Hepatitis D (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
2
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
3
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
4
Lonafarnib Investigational Phase 3 193275-84-2 148195
5 Immunologic Factors Phase 3
6 Anti-Infective Agents Phase 3
7 Antiviral Agents Phase 3
8 Interferon-alpha Phase 3
9 interferons Phase 3
10
protease inhibitors Phase 3
11 HIV Protease Inhibitors Phase 3
12 Cytochrome P-450 CYP3A Inhibitors Phase 3
13 Cytochrome P-450 Enzyme Inhibitors Phase 3
14
Ezetimibe Approved Phase 2 163222-33-1 150311
15
Ribavirin Approved Phase 2 36791-04-5 37542
16
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
17
Cetirizine Approved Phase 2 83881-51-0 2678
18
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
19
Histamine Approved, Investigational Phase 2 51-45-6 774
20
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
21
Chlorpheniramine Approved Phase 2 113-92-8, 132-22-9 2725
22
Hydroxyzine Approved Phase 2 68-88-2 3658
23
Coal tar Approved Phase 2 8007-45-2
24
Promethazine Approved, Investigational Phase 2 60-87-7 4927
25
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
26 Hypolipidemic Agents Phase 2
27 Anticholesteremic Agents Phase 2
28 Lipid Regulating Agents Phase 2
29 Adjuvants, Immunologic Phase 2
30 Antimetabolites Phase 2
31 Anti-Retroviral Agents Phase 2
32 Interferon alpha-2 Phase 2
33 Anti-HIV Agents Phase 2
34 Reverse Transcriptase Inhibitors Phase 2
35 Neurotransmitter Agents Phase 2
36 Histamine H1 Antagonists Phase 2
37
Histamine Phosphate Phase 2 51-74-1 65513
38 Histamine Antagonists Phase 2
39
Tipranavir Approved, Investigational Phase 1 174484-41-4 65027
40 Liver Extracts Phase 1
41 Iron-Dextran Complex Phase 1
42 Antibodies
43 Immunoglobulins
44 Hematinics
45 Anesthetics

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
2 A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis Completed NCT01088659 Phase 3 peginterferon alfa-2a [Pegasys];placebo;tenofovir
3 Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) in Patients With Chronic Hepatitis D (CHD) Completed NCT02732639 Phase 3 Pegylated Interferon (PEG-IFN) alfa-2a
4 An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron in naïve Patients With Chronic Hepatitis B and D Co-infection Completed NCT00686790 Phase 3
5 A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta Recruiting NCT03852719 Phase 3 Bulevirtide
6 A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR) Recruiting NCT03719313 Phase 3 Lonafarnib;Ritonavir;PEG IFN-alfa-2a;Placebo Lonafarnib;Placebo Ritonavir
7 Ezetimibe for Patients With Chronic Hepatitis D Unknown status NCT03099278 Phase 2 Ezetimibe
8 Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Unknown status NCT03105310 Phase 2 Pegylated interferon alfa;Ezetimibe
9 An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1) Completed NCT02430181 Phase 2 lonafarnib;PEG IFN-a;Ritonavir
10 An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2) Completed NCT02430194 Phase 2 lonafarnib;Ritonavir;PEG IFN-a
11 Treatment of Chronic Delta Hepatitis With Lonafarnib Completed NCT01495585 Phase 2 Lonafarnib
12 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Completed NCT02511431 Phase 2 Lonafarnib;Ritonavir
13 Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta Completed NCT02637999 Phase 1, Phase 2 PEG IFN alfa-2a;Myrcludex B
14 A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib in Combination With Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus Completed NCT02527707 Phase 2 lonafarnib;Ritonavir
15 Treatment of Chronic Delta Hepatitis With Pegylated Interferon Completed NCT00023322 Phase 2 Peginterferon Alpha-2a
16 A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Completed NCT03546621 Phase 2 Myrcludex B;Myrcludex-B;Myrcludex-B;Tenofovir
17 A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II) Completed NCT00932971 Phase 2 PEG-IFN alfa-2a, Tenofovir;PEG-IFN alfa-2a, placebo
18 A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT) Completed NCT02765802 Phase 2 Peginterferon Lambda-1A
19 Lamivudine for Chronic Hepatitis B Completed NCT00001457 Phase 2 Lamivudine
20 A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection Completed NCT02233075 Phase 2 REP 2139-Ca + Pegasys (TM)
21 A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D Completed NCT02731131 Phase 2 Peginterferon alfa-2a;Ribavirin
22 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Recruiting NCT03600714 Phase 2 Peg-interferon lambda;Lonafarnib;Ritonavir
23 A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta Recruiting NCT03852433 Phase 2 Bulevirtide;Peginterferon Alfa-2a
24 A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus (LOWR-5) Not yet recruiting NCT02968641 Phase 2 Lonafarnib;Ritonavir
25 A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH) Terminated NCT02577029 Phase 2 ARC-520;entecavir;tenofovir disoproxil;antihistamine
26 Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease Unknown status NCT01025622 Phase 1
27 Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
28 An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV) Terminated NCT01316185 Phase 1 EBP921
29 Serial HBV DNA Levels During Pregnancy in Patients With Chronic Hepatitis B: a Prospective Observational Follow-up Study Unknown status NCT01610115
30 Hepatitis D Virus Infection Among Hepatitis B Virus Surface Antigen Positive Individuals in Upper Egypt: Prevalence and Clinical Features Completed NCT04038372
31 Delta Hepatitis and Liver Disease in Hemophiliacs Completed NCT00005304
32 Prevalence and Consequences of Hepatitis Delta Virus Infection in Hemophiliacs Completed NCT00005305
33 Hepatitis D Virus (HDV) Mother-To-Child Transmission (MTCT) From Hepatitis B Virus (HBV)-Hepatitis D Virus (HDV) Co-infected Pregnant Women: a Retrospective Study. Completed NCT02044055
34 Hepatitis Delta Registry and Research Network- Observational Study Recruiting NCT02375906
35 Chronic Hepatitis B Virus Infection in Zambia: a Prospective Clinical Cohort Study Recruiting NCT03158818
36 Evaluation of Patients With Liver Disease Recruiting NCT00001971
37 A Long Term Follow-up Study of Patients From the REP 301 Protocol Active, not recruiting NCT02876419
38 HBV DNA Replication in Hepatocytes in HBV and HDV Co-infection Enrolling by invitation NCT04170452
39 Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis B Virus (HBV)/Hepatitis D Virus (HDV) Co-infection With Severe Fibrosis Injuries, or Moderate Fibrosis Injuries Associated With Persistent Increase of ALT Not yet recruiting NCT04166266
40 Epidemiology of Hepatitis B, C and Delta in Reunion Island Not yet recruiting NCT03362866
41 National, Multicenter, Observational Study Evaluating Prevalence, Virological and Clinical Characteristics of Chronic Hepatitis Delta in Romania and Assess Efficacy of Peg-interferon Alfa-2a Treatment in Patients With Chronic Hepatitis D (CHD) Terminated NCT01861444
42 A Nationwide Epidemiological, Non-Interventional Study Evaluating an Educational Support Program for Improving Treatment Adherence in Patients With Hepatitis B Viral Infection Withdrawn NCT01991262

Search NIH Clinical Center for Hepatitis D

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: hepatitis d

Genetic Tests for Hepatitis D

Anatomical Context for Hepatitis D

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis D:

19
Liver

MalaCards organs/tissues related to Hepatitis D:

40
Liver, T Cells, Testes, B Cells, Kidney, Lymph Node, Spleen

Publications for Hepatitis D

Articles related to Hepatitis D:

(show top 50) (show all 2675)
# Title Authors PMID Year
1
Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. 54 61
19914127 2010
2
Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. 54 61
19399797 2009
3
Capped small RNAs and MOV10 in human hepatitis delta virus replication. 54 61
18552826 2008
4
Treatment of chronic hepatitis D. 54 61
17958644 2007
5
The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome. 54 61
16959288 2007
6
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. 54 61
16911462 2006
7
A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles. 54 61
16641257 2006
8
Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. 54 61
16677149 2006
9
Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. 54 61
16091060 2005
10
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. 54 61
15188169 2004
11
Combinatorial control of human RNA polymerase II (RNAP II) pausing and transcript cleavage by transcription factor IIF, hepatitis delta antigen, and stimulatory factor II. 54 61
14506279 2003
12
Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. 54 61
12612062 2003
13
The double-stranded RNA-activated kinase, PKR, can phosphorylate hepatitis D virus small delta antigen at functional serine and threonine residues. 54 61
12060652 2002
14
Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. 54 61
11907222 2002
15
Stimulation of RNA polymerase II elongation by hepatitis delta antigen. 54 61
11387440 2001
16
Large isoform of hepatitis delta antigen activates serum response factor-associated transcription. 54 61
10961986 2000
17
[Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study]. 54 61
10377733 1999
18
Alpha-interferon treatment in HBeAg positive children with chronic hepatitis B and associated hepatitis D. 54 61
9782481 1998
19
Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. 54 61
9696491 1998
20
The nucleolin binding activity of hepatitis delta antigen is associated with nucleolus targeting. 54 61
9516470 1998
21
Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. 54 61
9500721 1998
22
Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. 54 61
9111310 1997
23
Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. 54 61
8871870 1996
24
RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. 54 61
8602246 1996
25
The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. 54 61
7776857 1995
26
Induction of the human gene for p44, a hepatitis-C-associated microtubular aggregate protein, by interferon-alpha/beta. 54 61
7925411 1994
27
Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of alpha 2b interferon. 54 61
7839006 1994
28
Treatment of chronic hepatitis D with interferon alfa-2a. 54 61
8259188 1994
29
The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. 54 61
8230419 1993
30
Chronic hepatitis in a large Indian hospital. 54 61
8241932 1993
31
Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells. 54 61
1328404 1992
32
High-throughput identification of synthetic riboswitches by barcode-free amplicon-sequencing in human cells. 61
32024835 2020
33
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply. 61
31990394 2020
34
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting. 61
31990393 2020
35
Hepatitis D prevalence: problems with extrapolation to global population estimates. 61
30567743 2020
36
Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. 61
31981726 2020
37
Hepatitis Delta Virus Alters the Autophagy Process To Promote Its Genome Replication. 61
31748400 2020
38
Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. 61
31964889 2020
39
Master of Disguise: Hepatitis Delta Virus Packaging and Spread Facilitated by Diverse Viral Envelope Proteins. 61
31465549 2020
40
Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. 61
31721254 2020
41
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? 61
31850558 2020
42
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply. 61
31850577 2020
43
Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 to 2019. 61
31469172 2020
44
High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort. 61
32000689 2020
45
The epidemiology of hepatitis delta virus infection in Cameroon. 61
31907297 2020
46
[The hepatitis delta virus: an easily turncoat pathogen?] 61
32014094 2020
47
Rescue of tomato spotted wilt virus entirely from complementary DNA clones. 61
31879355 2020
48
Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System. 61
31206195 2020
49
Prevalence of antibodies against Hepatitis D virus (HDV) in blood donors in Northern Germany. 61
31964608 2020
50
Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets. 61
30833451 2020

Variations for Hepatitis D

Expression for Hepatitis D

Search GEO for disease gene expression data for Hepatitis D.

Pathways for Hepatitis D

GO Terms for Hepatitis D

Biological processes related to Hepatitis D according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to virus GO:0009615 9.63 IFI44 EIF2AK2 ADAR
2 exogenous drug catabolic process GO:0042738 9.58 CYP2D6 CYP2C9
3 B cell differentiation GO:0030183 9.58 IFNA2 IFNA1 CD40LG
4 drug metabolic process GO:0017144 9.57 CYP2D6 CYP2C9
5 long-chain fatty acid biosynthetic process GO:0042759 9.56 CYP2D6 CYP2C9
6 organic acid metabolic process GO:0006082 9.55 CYP2D6 CYP2C9
7 T cell activation involved in immune response GO:0002286 9.54 IFNA2 IFNA1
8 type I interferon signaling pathway GO:0060337 9.54 IFNA2 IFNA1 ADAR
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.52 IFNA2 IFNA1
10 estrogen metabolic process GO:0008210 9.51 CYP2D6 CYP2C9
11 natural killer cell activation involved in immune response GO:0002323 9.49 IFNA2 IFNA1
12 oxidative demethylation GO:0070989 9.48 CYP2D6 CYP2C9
13 blood coagulation GO:0007596 9.46 IFNA2 IFNA1 HBE1 F2
14 response to interferon-alpha GO:0035455 9.43 EIF2AK2 ADAR
15 drug catabolic process GO:0042737 9.32 CYP2D6 CYP2C9
16 monoterpenoid metabolic process GO:0016098 9.26 CYP2D6 CYP2C9
17 B cell proliferation GO:0042100 9.13 IFNA2 IFNA1 CD40LG
18 defense response to virus GO:0051607 9.02 IFNL3 IFNA2 IFNA1 EIF2AK2 ADAR

Molecular functions related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.33 HBE1 CYP2D6 CYP2C9
2 type I interferon receptor binding GO:0005132 8.96 IFNA2 IFNA1
3 cytokine activity GO:0005125 8.92 IFNL3 IFNA2 IFNA1 CD40LG

Sources for Hepatitis D

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....